A pilot randomized controlled trial of acupuncture at the Si Guan Xue for cancer pain

To-Yi Lam¹, Li-Ming Lu², Wai-Man Ling³ and Li-Zhu Lin¹*

Abstracts

Background: Pain is a common symptom in cancer patients. Acupuncture is a suggested treatment for a wide range of clinical conditions, usually for its beneficial effects on pain control. Si guan xue (the four points) have been widely used in clinical practice, and has shown that it is highly effective, effective in obtaining qi, shows strong acupuncture stimulation, and is simple to manipulate and safe to use. Therefore, the aim of this study is to test the protocol and safety of acupuncture at the si guan xue in the management of cancer pain.

Methods: This is a single-blind, randomized controlled pilot trial. 42 patients with moderate to severe cancer pain were randomly assigned to three different arms with seven sessions of treatment; that is, treatment arm 1 (the si guan xue arm, n = 14), treatment arm 2 (the si guan xue plus commonly used acupoints arm, n = 14) and the control arm (the commonly used acupoints arm n = 14). Primary outcomes included acupuncture relieving cancer pain, and patients’ subjective improvement as measured by the Patient Global Impression of Change (PGIC). Secondary outcomes included the scores of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Karnofsky’s Performance Status (KPS).

Results: The analysis showed that the cancer pain reduction in treatment arm 2 was most prominent on day 5 when compared with the control arm (P<0.05). There was no difference in the scores of PGIC, EORTC QLQ-C30 or KPS among the three groups (P>0.05). Furthermore, no serious adverse events were observed.

Conclusions: These results indicate that acupuncture at the si guan xue plus commonly used acupoints tends to be effective in reducing cancer pain. However, the sample size was small, and a future multi-centre study with a larger sample size is warranted.

Trial registration: ChiCTR-IOR-15007471 (Retroactively registered on 28 NOV 2015)

Keywords: Acupuncture, Si guan Xue, Cancer pain, Randomized controlled trial

Background

Cancer is one of the world’s leading causes of death. According to recent reports, 12.7 million people diagnosed with cancer in 2008, and 7.6 million people died of it, accounting for 13% of all the deaths. It has been predicted that the total number of cancer deaths worldwide will increase from 13% in 2007 to 45% in 2030. For newly developed countries, the number is expected to increase from 11.3 million in 2007 to 15.5 million in 2030 [1].

Pain is a common cancer symptom. According to the World Health Organization (WHO) in 1995, there are 24.6 million cancer patients worldwide, 20% to 30% of whom suffer from various levels of pain. Although the three-step analgesic ladder of the WHO has been widely used, there is still a paucity of effective pain controls for many cancer patients, especially those in advanced stages of the disease. Many of these patients need to use analgesics such as opioids which act on the central nervous system. However, they may cause serious side effects, including nausea, vomiting, constipation, dryness

* Correspondence: lizhulin903@139.com
¹Department of Oncology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
of mouth, urinary retention, sleep disturbance, confusion, hallucinations, or even respiratory distress. They can give rise to intolerance among patients and coping difficulty for their families [2, 3].

Acupuncture is recommended for a wide range of clinical conditions. In particular, it has beneficial effects on pain control, and more importantly is safe to use. The benefits of acupuncture include rapid onset of analgesic effect, long sustained remission, ease of application, no risk of drug dependence or addiction, and by and large the absence of serious side effects [4].

Si guan xue is a unique combination of acupoints for acupuncture. It was first described in the "Twelve of the original nine-pin, Lingshu." It pointed out that "there are five zang and six fu. The six fu come from twelve original fu. The original twelve come from the si (four) guan. The si guan treat the five zang." Then Yang Jizhou, a famous Chinese Medicine Practitioner of the Ming Dynasty added that, "the si guan are Taichong (LR3) and Hegu (LI4)" [5]. The combination of these acupoints has the important effect of communicating the yin and yang, zang and fu, superior and inferior parts of the human body, and the qi and blood, and thus complementing each other. The si guan xue are widely used clinically. They have high treatment efficacy, easily get to the qi, are simple to manipulate, and safe to use [6, 7]. Their clinical use and efficacy for many clinical conditions are worthy of further studies. Therefore, this pilot study aims at testing the safety of acupuncture at the si guan xue in the management of cancer pain and informing the protocol for a larger study.

Methods
Settings and subjects
A pilot randomized clinical trial was conducted in the Department of Oncology at the First Affiliated Hospital of Guangzhou University of Chinese Medicine and at the OncWell Integrated Cancer Centre in Hong Kong.
The trial lasted from May 2012 to February 2014. The study protocol was approved by the Ethics Committee of Hong Kong East Cluster (Reference no.: HKEC-2012-024) before the start of the study. The reporting of the study complied with the requirements of the CONSORT 2010 statement [8].

Patients who fulfilled the following criteria were recruited into this study: (1) having advanced cancer with cancer pain as the chief complaint; (2) no chemotherapy or radiotherapy within one month before the study; (3) men or women aged 18 years or above; (4) levels of conscious to the extent that he/she could evaluate and report on their pain; (5) life expectancy of three months or above; and (6) capability of giving informed consent. Those with the following conditions were excluded: (1) pain was unrelated to cancer; (2) inability to report his/her pain accurately; (3) mental illness or lack capacity; (4) children or pregnant/lactating women; (5) other

Table 1 Baseline characteristics of patients ($n=45$)

| General Information | All patients | Participants | Hong Kong | Hong Kong |
|---------------------|-------------|--------------|-----------|-----------|
| Sex                 |             |              |           |           |
| Male                | 20 (47.62)  | 15 (50)      | 5 (41.67) | 0 (0)     |
| Female              | 22 (52.38)  | 15 (50)      | 7 (58.33) | 3 (100)   |
| Age                 |             |              |           |           |
| Average             | 57.59       | 56           | 59.17     | 78.33     |
| Range               | 24–91       | 24–79        | 42–91     | 74–82     |
| Marital status      |             |              |           |           |
| Single              | 2 (4.76)    | 0 (0)        | 2 (16.67) | 0 (0)     |
| Married             | 38 (90.48)  | 30 (100)     | 8 (66.66) | 2 (67)    |
| Widowed             | 2 (4.76)    | 0 (0)        | 2 (16.67) | 1 (33)    |
| Education           |             |              |           |           |
| Illiteracy          | 8 (19.05)   | 6 (20)       | 2 (16.67) | 1 (33)    |
| Primary school      | 13 (30.95)  | 12 (30)      | 1 (8.33)  | 1 (33)    |
| Secondary school    | 2 (4.76)    | 2 (6.67)     | 0 (0)     | 0 (0)     |
| High school         | 14 (33.33)  | 9 (30)       | 5 (41.67) | 1 (33)    |
| University or above | 5 (11.91)   | 1 (3.33)     | 4 (33.33) | 0 (0)     |
| Primary Disease Site|             |              |           |           |
| Head and neck       | 5 (11.9)    | 1 (3.33)     | 4 (33.33) | 1 (33)    |
| Lung                | 12 (28.57)  | 11 (36.67)   | 1 (8.33)  | 1 (33)    |
| Breast              | 3 (7.14)    | 1 (3.33)     | 2 (16.67) | 0 (0)     |
| Gynecological       | 6 (14.29)   | 5 (16.67)    | 1 (8.33)  | 0 (0)     |
| Liver               | 5 (11.9)    | 5 (16.67)    | 0 (0)     | 0 (0)     |
| Upper Gl (Esophagus, stomach and spleen) | 5 (11.9) | 3 (10)       | 2 (16.67) | 0 (0)     |
| Lower Gl (Colon)    | 3 (7.14)    | 2 (6.67)     | 1 (8.33)  | 0 (0)     |
| Other               | 3 (7.14)    | 2 (6.67)     | 1 (8.33)  | 1 (33)    |
| Stage of cancer     |             |              |           |           |
| III                 | 5 (11.9)    | 1 (3.33)     | 4 (33.33) | 0 (0)     |
| IV                  | 37 (88.1)   | 29 (96.67)   | 8 (66.67) | 3 (100)   |
| Other chronic diseases | 26 (61.9) | 20 (66.67)   | 6 (50)    | 2 (67)    |
| Level of pain       |             |              |           |           |
| Average             | 5.81        | 5.9          | 5.58      | 7         |
| Range               | 2–8         | 2–8          | 5–8       | 5–8       |
| KPS score           |             |              |           |           |
| Average             | 70          | 69           | 72.5      | 70        |
| Range               | 40–90       | 40–90        | 60–80     | 60–80     |
serious diseases; (6) unwillingness to cooperate or give informed consent [9–13].

Randomization and blinding
A computer program was used to randomize the participants [14]. The study coordinator was responsible for allocating the randomization codes that indicated the arms into the sequentially numbered and sealed envelopes. These envelopes were concealed from the investigators. In this pilot study, neither the investigators nor the participants were blinded, however the analyst was blinded.

Treatment procedures
The Chinese Medicine style of acupuncture was used. Acupuncture was conducted by two qualified Chinese Medicine Practitioners with nine and twelve years of experience in clinical practice, and three and ten years of acupuncture experience respectively. Both have bachelor’s and master’s degrees in Chinese Medicine related fields (one of whose master’s degrees is in acupuncture), and are well trained in acupuncture. A course of acupuncture with seven treatment sessions, delivered either daily or on alternating days, was given to the patients in the three arms. The standards of the study complied with the requirements of the Checklist for items in the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) 2010 [15].

Theoretical basis for using acupuncture to treat cancer pain
The design of our acupuncture treatment protocol was based on traditional Chinese Medicine theory. Pathophysiology of cancer pain, based on Western Medicine, did not affect the formulation of acupuncture interventions in this study. According to the Chinese medical diagnosis, diseases can be conceptualized as conditions of deficiency or strength. The former refers to the insufficiency of qi and blood, ying and yang, zang fu etc., whereas the latter implies a surplus of qi and blood. The normal circulation of qi and blood in the meridians requires warming by yang, moisturizing by yin, promotion by qi and the nourishment by blood. Deficiency of these elements leads to the malnutrition of zang fu, and then the pain. Deficiency is more prominent in advanced cancer patients [16, 17]. The si guan xue have been considered to have an important effect on communicating the yin and yang, zang and fu, superior and inferior parts of the human body, as well as the qi and blood. They thus complement each other. Hence, we hypothesized that si guan xue would enhance the treatment effects of the commonly used acupoints.

The choice of Acupoints
There were two treatment arms in the study. Treatment arm 1 used only the si guan xue, whereas treatment arm 2 used the si guan xue in combination with a set of

Table 2 Use of analgesics in the three study arms

| Use or not | Arm 1 (n = 14) | Control arm (n = 14) | Arm 2 (n = 14) | P-value |
|-----------|----------------|----------------------|----------------|---------|
| Yes       | 10             | 6                    | 7              | 0.287   |
| No        | 4              | 8                    | 7              |         |

Table 3 Types of analgesics used in the three study arms

| Drugs          | Arm 1 (n = 14) | Control arm (n = 14) | Arm 2 (n = 14) |
|----------------|----------------|----------------------|----------------|
| Morphine       | 0              | 3                    | 2              |
| Oxycodeone     | 3              | 1                    | 3              |
| Fentanyl patch | 3              | 3                    | 4              |
| Celecoxib      | 2              | 1                    | 1              |
| Tramadol       | 2              | 0                    | 0              |
| Carbamazepine  | 0              | 2                    | 1              |
| Meloxicam      | 0              | 1                    | 0              |

Note: P = 0.513

Table 4 Distribution of pain sites

| Pain sites       | Number of sites |
|------------------|-----------------|
| Head             | All             |
|                  | Mainland China  |
|                  | Hong Kong       |
| Head             | 2               | 0                | 2 |
| Neck and shoulder| 10              | 2                | 8 |
| Upper limb       | 8               | 1                | 7 |
| Upper back       | 12              | 8                | 4 |
| Lower back       | 10              | 8                | 2 |
| Chest            | 8               | 5                | 3 |
| Upper abdomen    | 7               | 5                | 2 |
| Lower abdomen    | 8               | 5                | 3 |
| Lower limb       | 20              | 11               | 9 |
| Other            | 5               | 2                | 3 |

Table 5 NRS on the level of pain over the previous 24 h

| Level of pain                  | All patients | Mainland China | Hong Kong |
|--------------------------------|--------------|----------------|-----------|
| Average of most severe pain    | 7.48         | 7.87           | 6.5       |
| Range                          | 3–10         | 5–10           | 3–9       |
| Average number of severe pain  | 4.74         | 4.3            | 5.83      |
| outbursts                      |              |                |           |
| Range                          | 0–9          | 1–8            | 0–9       |
| Average range of slightest pain| 3.1          | 2.93           | 3.5       |
| Range                          | 0–8          | 0–7            | 0–8       |
| Average pain                   | 5.62         | 5.73           | 5.33      |
| Range                          | 3–8          | 3–8            | 3–8       |
| Average current pain           | 5.8          | 5.9            | 5.58      |
| Range                          | 0–9          | 1–8            | 0–9       |
commonly used acupoints. This set of commonly used
acupoints, including Neiguan (PC6), Zusanli (ST36) and
Sanjinyjiao (SP6), were chosen according to a previous
extensive literature review [18–32]. They also consti-
tuted the control arm of the pilot study. All these
acupoints, especially those located below the elbow and
knee joints of the twelve regular meridians, have
therapeutic effects on diseases in both the local and the
remote regions.

**Acupuncture intervention**
Single-use acupuncture needles (0.25 x 25 mm or 0.30 x
40 mm) manufactured by MOCM International
Development Limited were inserted under the skin at
10-20 mm vertical depth. Then, a reinforcing-reducing
method was used to activate the qi until the sensation of
the arrival of qi (numbness, fullness and heaviness) was
reported by patients. Patients were maintained in supine
positions with the needles left in situ for 30 min. A
course of acupuncture treatment consisted of seven ses-
sions in total, performed either daily or on alternating
days. Safety precautions were conducted for the patients
before each treatment session to prevent acupuncture
related adverse events such as fainting, hematoma,
curved needles and broken needles.

**Clinical assessment**
The primary outcome of the study, the change in
pain, was evaluated by two methods. Firstly, it was
measured by the pain assessment form with a nu-
meric rating scale (NRS) from 0 to 10 (0 = the best,
10 = the worst) [33]. Secondly, patients’ subjective
improvement was assessed using the Patient Global
Impression of Change (PGIC) [34].

**Table 6** Changes of NRS reduction in the three study arms (\(\bar{x} \pm SD\))

| Time   | Arm 1 \((n = 14)\) | Control arm \((n = 14)\) | Arm 2 \((n = 14)\) | \(P\)-value |
|--------|-----------------|-----------------|-----------------|-----------|
| Day 1  | 1.93 ± 1.21     | 1.36 ± 1.15     | 1.86 ± 1.03     | 0.36      |
| Day 2  | 1.93 ± 1.14     | 1.14 ± 0.77     | 1.57 ± 1.28     | 0.17      |
| Day 3  | 1.93 ± 1.14     | 1.07 ± 1.07     | 1.64 ± 1.22     | 0.14      |
| Day 4  | 1.43 ± 1.16     | 1.21 ± 0.97     | 1.43 ± 1.02     | 0.83      |
| Day 5  | 1.36 ± 1.01     | 0.86 ± 0.86     | 1.79 ± 0.89\*   | 0.04      |
| Day 6  | 1.29 ± 1.14     | 0.93 ± 0.83     | 1.79 ± 1.19\*   | 0.11      |
| Day 7  | 1.36 ± 1.08     | 1.00 ± 1.04     | 1.29 ± 1.07     | 0.65      |

Main effect of time \((P\)-value)\* >0.05

\*There was no interaction between the changing trends in pain reduction scores and intervention factor of the three groups over time

\*Compared with the control group, the difference in cancer pain reduction scores was statistically significant, \(P<0.05\)
Secondary outcomes included the scores determined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [35] and the Karnofsky’s Performance Status (KPS). Three sets of EORTC QLQ-C30 were completed by the participants; that is, before the start of the study, after completing the 7th acupuncture treatment, and during the follow-up visit 2 weeks after the treatment. KPS was assessed on each follow-up visit.

Statistical analysis

The analyses were performed on the intention-to-treat population, defined as the participants who had completed baseline assessment and at least one evaluation after treatment. A repeated measures design approach was adopted to compare the treatment outcomes (the score of cancer pain reduction, Global Health Scale, Functional Scale, Symptom Scale and KPS) over time between the three groups. A model was established for performing longitudinal data analysis to explore the intervention effect and the time effect. Among-group differences at each measure time point were further examined using Analysis of Variance (ANOVA). Categorical variables, including categorical baseline variables and incidence of adverse events, were analyzed using a Chi-square ($\chi^2$) or Fisher Exact test. Statistical significance was defined as a two-tailed $P < 0.05$. Statistical analysis was performed by SPSS 20.0 (IBM SPSS Inc., Armonk, New York, USA) and SAS 9.2 software (SAS Institute Inc., Cary, USA).

Results

Baseline characteristics

1. General Information on the Accrued Patients

From May 2012 to February 2014, 45 cancer patients were screened. 3 refused to participate in this study because of geographical reasons or unwillingness to accept acupuncture. 42 participants (30 on the Mainland and 12 in Hong Kong) were randomly assigned to the three study arms with 14 in each of them (Fig. 1). 30 (71.4%) participants completed planned course of treatment. However, since all participants finished at least 2 sessions of treatment and at least 2 evaluations after treatment, they were all included in the data analysis.

Baseline characteristics of the patients are listed in Table 1. There were 20 men and 22 women. For patients on the Mainland, the majority had their primary cancer disease in the lung ($n = 11$), while it was in the head or neck for those in Hong Kong ($n = 4$). Most of the patients had stage IV cancer ($n = 37$), and some had been suffering from another chronic disease as well ($n = 26$) (Table 1). Before the acupuncture, the mean of pain score was 5.81, which was a moderate level of pain [33]. KPS was 70%, indicating that they could have lived independently, but could not have maintained normal activities or work [36]. Moreover, the use of analgesics was recorded for all accrued patients. There was no statistically significant difference in analgesic use among the three study arms ($P > 0.05$) (Tables 2 and 3).

Information on pain patients before treatment

The number of pain sites for each participant ranged from 1 to 7. There were 90 pain sites in total. Most were located on the lower limbs ($n = 20$) (Table 4). The average NRS pain score over the previous 24 h before acupuncture was 5.62. Nonetheless, the average NRS score for the most severe pain was as high as 7.48, which was defined as “severe” according to the NRS. The occurrence of this severe NRS pain score was 4.74 on average. The average for even the slightest NRS pain score was 5.62. Nonetheless, the average NRS pain score before acupuncture was 5.8, a moderate level of pain [33].

Table 7 PGIC scores in the three study arms ($\bar{x} \pm SD$)

| Time    | Arm 1 (n = 14) | Control arm (n = 14) | Arm 2 (n = 14) | P-value |
|---------|----------------|----------------------|---------------|---------|
| Day 7   | 2.42 ± 0.79    | 2.64 ± 0.67          | 2.56 ± 0.53   | 0.74    |

*There was no interaction between the changing trends of PGIC scores and the three groups’ intervention factors over time.

Table 8 Global health score and changes in the three study arms ($\bar{x} \pm SD$)

| Time          | Arm 1 (n = 14) | Control arm (n = 14) | Arm 2 (n = 14) | P-value |
|---------------|----------------|----------------------|---------------|---------|
| Baseline      | 39.88 ± 19.39  | 32.74 ± 18.90        | 35.12 ± 15.04 | 0.57    |
| Day 7         | 50.60 ± 17.13  | 44.64 ± 20.83        | 48.81 ± 16.62 | 0.68    |
| Follow up     | 50.60 ± 19.47  | 45.24 ± 16.89        | 46.43 ± 18.98 | 0.73    |
| Main effect of time ($P$-value)* | <0.05 |

*There was no interaction between the changing trends in Global Health scores and the three groups’ intervention factors over time.

Table 9 Functional scale score and changes in the three study arms ($\bar{x} \pm SD$)

| Time          | Arm 1 (n = 14) | Control arm (n = 14) | Arm 2 (n = 14) | P-value |
|---------------|----------------|----------------------|---------------|---------|
| Baseline      | 90.29 ± 4.00   | 87.24 ± 3.89         | 88.60 ± 3.56  | 0.12    |
| Day 7         | 91.56 ± 4.94   | 89.21 ± 4.16         | 90.35 ± 4.10  | 0.38    |
| Follow up     | 90.79 ± 4.85   | 89.78 ± 3.53         | 90.48 ± 4.27  | 0.81    |
| Main effect of time ($P$-value)* | <0.05 |

*There was no interaction between the changing trends of Functional scale scores and the three groups’ intervention factors over time.
Primary outcome
According to analysis of the seven treatment sessions, the magnitude of pain score reduction tended to decrease in both treatment arm 1 and control arm, while it increased in treatment arm 2 (Fig. 2). For the among-group comparisons at each time point, there was a statistically significant improvement in the pain score in treatment arm 2 on the fifth day of treatment (Table 6) ($P<0.05$). There was no difference among the three groups observed in a repeated measures design approach.

On the other hand, for the patients’ perception of the overall improvement, the results of PGIC measurement across the three arms revealed that the difference in their PGIC scores was not statistically significant ($P > 0.05$) (Table 7).

Secondary outcomes
Both the Global Health Scale and the Functional Scale increased during the treatment course (Tables 8, 9 and Fig. 3), whereas the Symptom Scale decreased (Table 10). However, there was no statistically significant difference found across the three arms in all the EORTC QLQ-C30 domains ($P > 0.05$). Additionally, no difference between the three groups was observed in a repeated measures design approach.

The KPS score of the three arms showed an increasing trend during the treatment course, but the difference across the three arms was not statistically significant ($P>0.05$) (Table 11 and Fig. 4).

Safety analysis
The safety of acupuncture, including acupuncture related fainting, hematoma, curved and broken needles was also examined in the pilot study. Throughout the study period, no serious acupuncture-related adverse events occurred. There was only one reported episode of mild local bruising, at one acupuncture site, which was successfully managed with direct digital pressure administered by the practitioner.

Discussion
Acupuncture may be useful in controlling the pain experienced by many cancer patients. It is a complementary and conservative therapy that balances the flow of vital energy, and in turn helps to relieve pain. It is an analgesic adjunctive method for cancer patients that is worthy of additional high quality studies [37–39].

Because of the small sample size, this pilot study mainly intends to examine the preliminary effects of the

Table 10 Symptom scale score and changes in the three study arms ($\bar{x} \pm SD$)

| Time                  | Arm 1 $(n = 14)$ | Control arm $(n = 14)$ | Arm 2 $(n = 14)$ | $P$-value |
|-----------------------|------------------|------------------------|------------------|-----------|
| Baseline              | 4.46 ± 1.59      | 5.45 ± 1.88            | 5.21 ± 1.86      | 0.32      |
| Day 7                 | 3.36 ± 2.39      | 3.93 ± 1.90            | 4.17 ± 1.92      | 0.57      |
| Follow up             | 3.72 ± 2.02      | 3.91 ± 1.78            | 4.27 ± 2.10      | 0.28      |

Main effect of time ($P$-value)* $<0.05$

*There was no interaction between the changing trends of Symptom scale scores and the three groups’ intervention factors over time.
acupuncture protocol using the si guan xue for cancer pain management for a larger study and its safety. The primary outcomes were the trend of acupuncture in relieving cancer pain and patients’ subjective improvement as measured by the PGIC. Secondary outcomes were patients’ well-being as determined by the EORTC QLQ-C30 and the KPS. According to the data analysis, the effect of pain relief tended to decrease in treatment arm 1 (si guan xue only) and the control arm (commonly used acupoints only). However, it increased in treatment arm 2 (a combination of si guan xue and commonly used acupoints), especially on the fifth day of treatment. This phenomenon reflects the fact that acupuncture treatment takes time to accumulate and exert its analgesic effect, which is consistent with the clinical experience of our routine practice [40]. On the other hand, although the trend of analgesic effect was still observed on days 6 and 7, it was not statistically significant. This may be due to the sample size of the pilot study, which is too small to detect any sustained effect.

Also, it revealed that either the acupuncture at si guan xue or commonly used acupoints are effective in reducing cancer pain, but that the combination of these two appears to further enhance pain reduction. Thus, this seemed to be a better acupuncture protocol for cancer pain management. There are several possible explanations for this enhanced effect. Firstly, a special technique of acupuncture was used in treatment arm 2. The si guan xue was opened first before regulating the commonly used acupoints. It had been recognized that this technique could produce a stronger clinical effect [41, 42]. Secondly, previous studies had suggested that acupuncture at the si guan xue could activate the qi, replenish the vital substances of the body and strengthen the visceral organs [6, 7]. Thirdly, several other studies have also supported the claim that acupuncture at the si guan xue could give rise to sedative, antispasmodic and analgesic effects. Thus, the use of the si guan xue would be more effective in controlling cancer pain [43, 44]. Though it was limited to patients with liver cancer, there has been one randomized controlled study of acupuncture at the si guan xue. It enrolled 86 patients and revealed that acupuncture achieved a better control on cancer pain than codeine treatment [45]. The results of our pilot study are not only consistent with these previous findings, but also reveal that the beneficial effect on cancer pain is applicable to other cancer-related diseases.

Table 11 KPS score and changes in the three study arms (\(\bar{x} \pm SD\))

| Time  | Arm 1 (n = 14) | Control arm (n = 14) | Arm 2 (n = 14) | P-value |
|-------|---------------|---------------------|---------------|---------|
| Day 1 | 70.00 ± 15.19 | 72.86 ± 13.83      | 67.14 ± 9.14  | 0.51    |
| Day 2 | 70.00 ± 15.19 | 72.86 ± 13.83      | 67.14 ± 9.14  | 0.51    |
| Day 3 | 70.00 ± 15.19 | 73.57 ± 13.36      | 67.86 ± 9.75  | 0.51    |
| Day 4 | 70.00 ± 15.19 | 73.57 ± 13.36      | 68.57 ± 9.49  | 0.57    |
| Day 5 | 70.71 ± 14.92 | 73.57 ± 13.36      | 68.57 ± 9.49  | 0.59    |
| Day 6 | 70.71 ± 14.92 | 73.57 ± 13.36      | 68.57 ± 9.49  | 0.59    |
| Day 7 | 70.71 ± 14.92 | 73.57 ± 13.36      | 68.57 ± 9.49  | 0.59    |

Main effect of time (P-value)*

*There was no interaction between the changing trends of the KPS scores and the three groups’ intervention factors over time.

Fig. 4 KPS score and changes among the 3 groups. (Group 1: Treatment arm 1; Group 2: Control group; Group 3: Treatment Arm 2)
There was no statistically significant difference found across the three arms in the PGIC, EORTC QLQ-C30, and KPS scores ($P>0.05$). A possible explanation is that the treatment and evaluation period was too short to reveal the full effect of the acupuncture. However, these clinical outcomes might require longer observation times to see improvement, as documented by these scores. Therefore, the clinicians should contemplate the appropriate duration of acupuncture treatment for cancer pain. A course of 14 acupuncture sessions, or at least 2 weeks of treatment is needed for better management of this problem [40, 46]. In addition, the small sample size is another possible factor accounting for the negative results in the above outcomes.

**Limitations of the pilot study**

As mentioned above, the main limitation of this study was the small sample size, which was inadequate to confirm the efficacy of acupuncture in the management of cancer pain. Moreover, the treatment and observation time were too short to reveal the full effect of the acupuncture. Seven patients even requested to continue their acupuncture treatment upon completion of the study. This may reflect the fact that acupuncture at the *si guan xue* helps to control their cancer pain and improve their quality of life, but a longer treatment course remains more desirable.

**Conclusion**

The results of this pilot study indicate that acupuncture at the *si guan xue* plus commonly used acupoints tends to be effective in reducing cancer pain. It may also be beneficial in controlling cancer pain in advanced cancer patients. The use and addition of the *si guan xue* in acupuncture for cancer pain has also been found to be feasible and manageable. Although no firm conclusions can be drawn from such an under-powered study, it did show a trend towards an improvement in cancer pain scores. Therefore, further large scale and multi-centre randomized controlled trials of the *si guan xue* plus commonly used acupoints are warranted to confirm its treatment efficacy.

**Abbreviations**

ANOVA: Analysis of variance; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; KPS: Karnofsky's Performance Status; NRS: Numeric rating scale; PGIC: Patient global impression of change; STRICTA: Standards for reporting interventions in clinical trials of acupuncture; WHO: World health organization

**Acknowledgements**

Not applicable.

**Funding**

There is no external funding for this study. The authors have no financial relationships to disclose.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.

**Authors’ contributions**

TYL and LZZ designed and led the entire study; TYL and WML analyzed and interpreted the patient data for generating the study results. TYL and WML drafted the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

The consent form for the study participants was incorporated into the study protocol, and was approved by the Ethics Committee of Hong Kong East Cluster. Study consent, including that for data publication, was obtained from each participant prior to joining the study.

**Ethics approval and consent to participate**

The study protocol was approved by the Ethics Committee of Hong Kong East Cluster (Reference no.: HKEC-2012-024) before the start of this study. The informed consent to participate in our study was obtained from all participants prior to their involvement.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Department of Oncology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. 2. The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China. 3. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Road, Chai Wan, Hong Kong.

Received: 20 November 2016 Accepted: 13 June 2017

**Published online:** 26 June 2017

**References**

1. World Health Organization. Is the number of cancer patients in the world increasing or decreasing? http://www.who.int/features/cancer/ztv. Accessed 15 July 2013.
2. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management: stepping up the quality of its evaluation. The Journal of the American Medical Association. 1995;274(23):1870-3.
3. Cherry NL. The Management of Cancer Pain. CA-A Cancer Journal for Clinicians. 2000;50(2):72–3.
4. Johnstone PAS, Polston GR, Martin PJ. Integration of acupuncture into the oncology clinic. Palliat Med. 2002;16:235–9.
5. Yin J, Longxiang H, Jiahou Y. The culmination of Acupuncture. Beijing: People's Medical Publishing House. 2010;47.
6. Geng T. Meta clinical experience of si guan xue. Journal of Inner Mongolia Traditional Chinese Medicine. 2007;9:49–51.
7. Jing H, Liu C. Clinical application of si guan xue. Journal of Jilin Traditional Chinese Medicine. 2005;25(4):34.
8. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
9. Wang R, Zhu Y, Hongwen J, et al. Investigation of cancer pain treatment in 43 cases [J]. Chinese Medicine. 2002;9:39
10. Chen H, Jun P. Clinical observation on the efficacy of integrative treatment of bone metastases pain in 25 cases [J]. Journal of Fujian Traditional Chinese Medicine. 2008;29(10):12–3.
11. Wang H, Wang Y-h. Chinese medicine combined with chemotherapy in the treatment of advanced breast cancer bone metastasis pain in 53 cases [J]. Journal of Fujian Traditional Chinese Medicine. 2001;32(5):12.
13. Dong J, Li Q. Clinical observation on the efficacy of integrative treatment of bone metastases pain in 27 cases (JJ. Journal of Henan Medical College. 2010;22(2):575–7.

14. Urbaniaik GC, Plous S. Research Randomizer (Version 4.0) [Computer software]. http://www.randomizer.org/form.html. Accessed 22 December 2011.

15. MacPherson H, Atkinson DG, Hammerschlag R, et al. Revised standards for reporting interventions in clinical trials of acupuncture (STRICTA): extending the CONSORT statement. PlcO Med. 2010;7(6):e1000261.

16. Liu Z, Liang L. Essentials of Chinese medicine volume 1. New York: Springer-Verlag London Limited. 2009:284–8.

17. Li Y, Wenbin F. Pain caused by healthy qi deficiency and its management with moxibustion. Hong Kong: Proceedings of the International Academic Seminar of Acuomoxa in Pain Management. 2009;5:355–8.

18. Zhang W. Acupuncture treatment of cancer pain in 160 cases. Emergency of Chinese Medicine of China. 2008;17(4):543–4.

19. Gao Z, Xiaohuang XBQR, et al. Clinical observation on the efficacy of combination of acupuncture and topical treatment of cancer pain. Practical Journal of Chinese Medicine. 1998;11:7.

20. Jinhua X. The combination of electroacupuncture with the three-step analgesia for the treatment of cancer pain in 15 cases. Shanghai Journal of Acupuncture. 1999;18(5):21.

21. GuiPing Chen, Jinhong Yang, Mei Juan Yu, et al. Acupuncture treatment of radiotherapy and chemotherapy gastrointestinal reactions in 44 cases. Chinese acupuncture and moxibustion, 1996;16(7):9.

22. Hong Mu, Qu Bin Zheng, Wei Zhu Yang, et al. Observation on therapeutic effect of acupuncture of Neiguan in complications of interventional treatment on hepatic carcinoma. Chinese Journal of Integrated Chinese and Western Medicine, 1995,16(10):611.

23. Dong W, Yang J. Observation on acupuncture analgesic effect of cancer pain. Practical Journal of Chinese Medicine. 1999;15(7):28.

24. Deng L. Acupuncture treatment of hepatocellular carcinoma after interventional chemotherapy induced hiccups. Shanxi Chinese Medicine. 1997;13(2):42.

25. Yu D. The clinical study of acupuncture of analgesic effect on cancer pain. Chinese acupuncture and moxibustion. 1998;1(18):17.

26. Bian R. The clinical study of acupuncture treatment on cancer pain of stomach cancer. Journal of Chinese Medicine. 1995;36(3):277–80.

27. Wu B, Zhou R, He K. Research status and prospects of acupuncture and moxibustion regulating immunological function. Shanghai Journal of Acupuncture and moxibustion. 1999;18(1):46.

28. Chen X. Clinical and experimental research survey of acupuncture and moxibustion on antitumor effect. Hubei Journal of Chinese Medicine. 1998;5:59.

29. Gao X. Observation on acupuncture analgesic effect of cancer pain. Practica Journal of Chinese Medicine. 1999;15(7):28.

30. Sun YL, Yu LR. Observation on the therapeutic effect and nursing care of acupuncture combined with three-step analgesic ladder treatment of cancer pain. Modern Nursing. 2002;8(8):588.

31. Sun YL, Yu LR. Observation on the therapeutic effect of needle-retaining method of triple acupuncture in 80 cases of pain due to liver cancer. Chin Acupuc Moxibustion. 2000;21:211–2.

32. Lee H, Schmidt K, Ernst E. Acupuncture for the relief of cancer-related pain: a systematic review. European Journal of Pain. 2005;9(4):437–444.

33. Johnstone PA, Polston GR, Nienitzow RC, Martin PJ. Integration of acupuncture into the oncology clinic. Palliat Med. 2002;16(3):235–9.

34. Cho H, Lee MS, Kim T. Acupuncture for the treatment of cancer pain: a systematic review of randomized clinical trials. Support Care Cancer. 2012;20:1147–58.

35. Ming X. Experience on clinical application “si guan xue”. Practical Journal of Chinese Medicine. 2006;22(5):300.

36. Ja YJ. Preliminary knowledge on opening of si guan xue. Chinese Medicine of Shanxi. 2008;29(8):1103–4.

37. Cheng T. Meta clinical experience on si guan xue. Inner Mongolia Traditional Chinese Medicine. 2007;9:49–51.

38. Hyangsook Lee, Katja Schmidt, Edzard Ernst. Acupuncture for the relief of cancer-related pain – a systematic review. European Journal of Pain. 2005;9(4):437–444.

39. Johnstone PA, Polston GR, Nienitzow RC, Martin PJ. Integration of acupuncture into the oncology clinic. Palliat Med. 2002;16(3):235–9.

40. Choi T, Lee MS, Kim T. Acupuncture for the treatment of cancer pain: a systematic review of randomized clinical trials. Support Care Cancer. 2012;20:1147–58.